T2 Biosystems, Inc. (NASDAQ:TTOO) Q1 2024 Earnings Call Transcript

John Sperzel: Absolutely. So we’ve talked publicly about Candida Auris. And every time we talk to a customer almost without exception about our T2Candida Panel. We are asked about the addition of Canada Auris, including at the ECCMID conference in our booth regularly over the last week or so. And so we think we’re on the right track in adding Canada Auris to our T2Candida Panel. The test itself has FDA breakthrough device designation. And that’s an area where we think there will be funding to help us get that over the goal line of sort of non-dilutive grant based type funding. There may also be that type of funding for adding additional targets on a tick-borne panel. That’s something we’re also exploring in the early stages.

Kyle Mikson: Got you. Okay. That makes sense over there. Thanks, appreciate it.

Operator: We have no further questions in queue. I will now turn the call over to John Sperzel for closing remarks.

John Sperzel: Thank you very much for joining our Q1 earnings call. We appreciate your support, and we look forward to updating you next quarter. Have a great afternoon.

Operator: This concludes today’s conference, and you may disconnect your lines at this time. Thank you for your participation.+